联系我们

论文查询结果	返回搜索

论文编号：	15470
作者编号：	2320224104
上传时间：	2025/6/12 11:01:28
中文题目：	新政策环境下M医药公司HPV疫苗营销策略研究
英文题目：	The Research on the Marketing Strategy of HPV vaccine of M Pharmaceutical Company under the New Policy Environment
指导老师：	张永强教授
中文关键字：	HPV疫苗；宫颈癌；营销策略
英文关键字：	HPV vaccine; Cervical cancer; Marketing strategy.
中文摘要：	宫颈癌作为全球第四大女性恶性肿瘤，其防控已上升至国家公共卫生战略高度。2024 年国家癌症中心数据显示，我国宫颈癌年新发病例达 15.1 万例，且呈现年轻化趋势。世界卫生组织《加速消除宫颈癌全球战略》及我国《加速消除宫颈癌行动计划（2023-2030）》的实施，为 HPV 疫苗市场带来政策红利的同时，也对企业营销策略提出新要求。本文以 M 医药公司为研究对象，运用 STP 理论与 4P 营销组合框架，系统分析其在政策驱动下的营销环境与竞争格局，探讨新政策环境下营销策略优化构想。 研究发现，M 医药公司凭借九价 HPV 疫苗的技术优势（覆盖 9 种 HPV 型别，保护率达 90%）及男性适应证先发优势，在高端市场保持领先地位，但面临其他HPV疫苗低价竞争（如万泰生物二价疫苗价格降至 86 元 / 剂）、多元化推广策略（如万泰生物及GSK二价HPV疫苗在特定人群中实施“打两针免费一针”推广策略）及供应链波动等挑战。基于 SWOT 分析，提出 "技术领先 + 男女共防" 的差异化定位策略：在女性市场推行 "两针次接种 + 公益补贴" 组合方案，在男性市场构建 "政企协同 + 健康科普" 推广模式。结合 4P 理论，建议优化产品组合、实施分层定价（政府采购折扣与高端市场溢价）、拓展数字化渠道（微信预约 + 社区接种点）及强化公益营销（贝壳行动覆盖 9000 万妇女）等营销策略。 研究表明，M 医药公司需通过 "技术壁垒巩固 - 政策红利转化 - 数字化能力提升" 三维路径实现可持续发展，其策略创新不仅为企业突破市场瓶颈提供解决方案，更为疫苗行业应对政策变革与技术迭代提供理论参考。
英文摘要：	As the fourth largest malignant tumor among women globally, the prevention and control of cervical cancer has been elevated to the level of national public health strategy. Data from the National Cancer Center in 2024 indicate that the annual incidence of cervical cancer in China has reached 151,000 cases, with a trend toward younger populations. The implementation of the World Health Organization's “Global Strategy to Accelerate the Elimination of Cervical Cancer” and "Accelerated Action Plan for the Elimination of Cervical Cancer (2023-2030)" has not only brought policy dividends to the HPV vaccine market but also introduced new requirements for corporate marketing strategies. This paper focuses on M Pharmaceutical as the research subject and systematically analyzes the marketing environment and competitive landscape under policy drivers using STP theory and the 4P marketing mix framework.The study finds that M Pharmaceutical maintains a leading position in the high-end market due to the technological advantages of the 9-valent HPV vaccine (which covers 9 types of HPV with a 90% protection rate) and the first-mover advantage for male indications; however, it faces challenges such as low-price competition from other HPV vaccines (for instance, Wantai Bio's bivalent vaccine price has dropped to 86 yuan per dose), diversified promotional strategies (like Wantai Biopharma and GSK's implementation of a 'two shots for the price of one' promotion in specific populations), and supply chain fluctuations. Based on the SWOT analysis, it proposes a differentiated positioning strategy of 'leading technology + common defense for both genders': implementing a combination of 'two-dose vaccination + public welfare subsidy' in the female market, and constructing a promotion model of 'government-enterprise collaboration + health education' in the male market. In conjunction with the 4P theory, it is recommended to optimize the product mix, implement tiered pricing (government procurement discounts and premiums in the high-end market), expand digital channels (WeChat appointments + community vaccination sites), and strengthen cause-related marketing (the Beike initiative covers 90 million women).The research indicates that M Pharmaceutical must achieve sustainable development through a three-dimensional approach of 'consolidating technical barriers, transforming policy dividends, and enhancing digital capabilities.' This strategic innovation not only provides solutions for companies to overcome market bottlenecks but also offers a theoretical reference for the vaccine industry to cope with policy changes and technological iterations.
查看全文：	预览  下载(下载需要进行登录)